Kaličanin, Nevena

Link to this page

Authority KeyName Variants
orcid::0000-0003-0146-1514
  • Kaličanin, Nevena (2)
Projects

Author's Bibliography

Inhibition of SARS-CoV-2 Mpro with Vitamin C, L-Arginine and a Vitamin C/L-Arginine Combination

Đukić, Ivana; Kaličanin, Nevena; Senćanski, Milan V.; Pajović, Snežana B.; Milićević, Jelena S.; Prljić, Jelena; Paessler, Slobodan; Prodanović, Radivoje; Glišić, Sanja

(2023)

TY  - JOUR
AU  - Đukić, Ivana
AU  - Kaličanin, Nevena
AU  - Senćanski, Milan V.
AU  - Pajović, Snežana B.
AU  - Milićević, Jelena S.
AU  - Prljić, Jelena
AU  - Paessler, Slobodan
AU  - Prodanović, Radivoje
AU  - Glišić, Sanja
PY  - 2023
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/10629
AB  - Drug resistance is a critical problem in health care that affects therapy outcomes and requires new approaches to drugdesign. SARS-CoV-2 Mpro mutations are of concern as they can potentially reduce therapeutic efficacy. Viral infections are amongst themany disorders for which nutraceuticals have been employed as an adjunct therapy. The aim of this study was to examine the potentialin vitro activity of L-arginine and vitamin C against SARS-CoV-2 Mpro. Methods: The Mpro inhibition assay was developed by cloning,expression, purification, and characterization of Mpro. Selected compounds were then screened for protease inhibition. Results: Largininewas found to be active against SARS-CoV-2 Mpro, while a vitamin C/L-arginine combination had a synergistic antiviral actionagainst Mpro. These findings confirm the results of our previous in silico repurposing study that showed L-arginine and vitamin C werepotential Mpro inhibitors. Moreover, they suggest a possible molecular mechanism to explain the beneficial effect of arginine in COVIDpatients. Conclusions: The findings of the current study are important because they help to identify COVID-19 treatments that areefficient, inexpensive, and have a favorable safety profile. The results of this study also suggest a possible adjuvant nutritional strategyfor COVID-19 that could be used in conjunction with pharmacological agents.
T2  - Frontiers in Bioscience - Landmark
T1  - Inhibition of SARS-CoV-2 Mpro with Vitamin C, L-Arginine and a Vitamin C/L-Arginine Combination
VL  - 28
IS  - 1
SP  - 8
DO  - 10.31083/j.fbl2801008
ER  - 
@article{
author = "Đukić, Ivana and Kaličanin, Nevena and Senćanski, Milan V. and Pajović, Snežana B. and Milićević, Jelena S. and Prljić, Jelena and Paessler, Slobodan and Prodanović, Radivoje and Glišić, Sanja",
year = "2023",
abstract = "Drug resistance is a critical problem in health care that affects therapy outcomes and requires new approaches to drugdesign. SARS-CoV-2 Mpro mutations are of concern as they can potentially reduce therapeutic efficacy. Viral infections are amongst themany disorders for which nutraceuticals have been employed as an adjunct therapy. The aim of this study was to examine the potentialin vitro activity of L-arginine and vitamin C against SARS-CoV-2 Mpro. Methods: The Mpro inhibition assay was developed by cloning,expression, purification, and characterization of Mpro. Selected compounds were then screened for protease inhibition. Results: Largininewas found to be active against SARS-CoV-2 Mpro, while a vitamin C/L-arginine combination had a synergistic antiviral actionagainst Mpro. These findings confirm the results of our previous in silico repurposing study that showed L-arginine and vitamin C werepotential Mpro inhibitors. Moreover, they suggest a possible molecular mechanism to explain the beneficial effect of arginine in COVIDpatients. Conclusions: The findings of the current study are important because they help to identify COVID-19 treatments that areefficient, inexpensive, and have a favorable safety profile. The results of this study also suggest a possible adjuvant nutritional strategyfor COVID-19 that could be used in conjunction with pharmacological agents.",
journal = "Frontiers in Bioscience - Landmark",
title = "Inhibition of SARS-CoV-2 Mpro with Vitamin C, L-Arginine and a Vitamin C/L-Arginine Combination",
volume = "28",
number = "1",
pages = "8",
doi = "10.31083/j.fbl2801008"
}
Đukić, I., Kaličanin, N., Senćanski, M. V., Pajović, S. B., Milićević, J. S., Prljić, J., Paessler, S., Prodanović, R.,& Glišić, S.. (2023). Inhibition of SARS-CoV-2 Mpro with Vitamin C, L-Arginine and a Vitamin C/L-Arginine Combination. in Frontiers in Bioscience - Landmark, 28(1), 8.
https://doi.org/10.31083/j.fbl2801008
Đukić I, Kaličanin N, Senćanski MV, Pajović SB, Milićević JS, Prljić J, Paessler S, Prodanović R, Glišić S. Inhibition of SARS-CoV-2 Mpro with Vitamin C, L-Arginine and a Vitamin C/L-Arginine Combination. in Frontiers in Bioscience - Landmark. 2023;28(1):8.
doi:10.31083/j.fbl2801008 .
Đukić, Ivana, Kaličanin, Nevena, Senćanski, Milan V., Pajović, Snežana B., Milićević, Jelena S., Prljić, Jelena, Paessler, Slobodan, Prodanović, Radivoje, Glišić, Sanja, "Inhibition of SARS-CoV-2 Mpro with Vitamin C, L-Arginine and a Vitamin C/L-Arginine Combination" in Frontiers in Bioscience - Landmark, 28, no. 1 (2023):8,
https://doi.org/10.31083/j.fbl2801008 . .
1
1
1

In Silico and In Vitro Inhibition of SARS-CoV-2 PLpro with Gramicidin D

Protić, Sara; Kaličanin, Nevena; Senćanski, Milan; Prodanović, Olivera; Milićević, Jelena S.; Perović, Vladimir; Paessler, Slobodan; Prodanović, Radivoje; Glišić, Sanja

(2023)

TY  - JOUR
AU  - Protić, Sara
AU  - Kaličanin, Nevena
AU  - Senćanski, Milan
AU  - Prodanović, Olivera
AU  - Milićević, Jelena S.
AU  - Perović, Vladimir
AU  - Paessler, Slobodan
AU  - Prodanović, Radivoje
AU  - Glišić, Sanja
PY  - 2023
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/10644
AB  - Finding an effective drug to prevent or treat COVID-19 is of utmost importance in tcurrentpandemic. Since developing a new treatment takes a significant amount of time, drug repurposingcan be an effective option for achieving a rapid response. This study used a combined in silico virtualscreening protocol for candidate SARS-CoV-2 PLpro inhibitors. The Drugbank database was searchedfirst, using the Informational Spectrum Method for Small Molecules, followed by molecular docking.Gramicidin D was selected as a peptide drug, showing the best in silico interaction profile with PLpro.After the expression and purification of PLpro, gramicidin D was screened for protease inhibitionin vitro and was found to be active against PLpro. The current study’s findings are significantbecause it is critical to identify COVID-19 therapies that are efficient, affordable, and have a favorablesafety profile.
T2  - International Journal of Molecular Sciences
T1  - In Silico and In Vitro Inhibition of SARS-CoV-2 PLpro with Gramicidin D
VL  - 24
IS  - 3
SP  - 1955
DO  - 10.3390/ijms24031955
ER  - 
@article{
author = "Protić, Sara and Kaličanin, Nevena and Senćanski, Milan and Prodanović, Olivera and Milićević, Jelena S. and Perović, Vladimir and Paessler, Slobodan and Prodanović, Radivoje and Glišić, Sanja",
year = "2023",
abstract = "Finding an effective drug to prevent or treat COVID-19 is of utmost importance in tcurrentpandemic. Since developing a new treatment takes a significant amount of time, drug repurposingcan be an effective option for achieving a rapid response. This study used a combined in silico virtualscreening protocol for candidate SARS-CoV-2 PLpro inhibitors. The Drugbank database was searchedfirst, using the Informational Spectrum Method for Small Molecules, followed by molecular docking.Gramicidin D was selected as a peptide drug, showing the best in silico interaction profile with PLpro.After the expression and purification of PLpro, gramicidin D was screened for protease inhibitionin vitro and was found to be active against PLpro. The current study’s findings are significantbecause it is critical to identify COVID-19 therapies that are efficient, affordable, and have a favorablesafety profile.",
journal = "International Journal of Molecular Sciences",
title = "In Silico and In Vitro Inhibition of SARS-CoV-2 PLpro with Gramicidin D",
volume = "24",
number = "3",
pages = "1955",
doi = "10.3390/ijms24031955"
}
Protić, S., Kaličanin, N., Senćanski, M., Prodanović, O., Milićević, J. S., Perović, V., Paessler, S., Prodanović, R.,& Glišić, S.. (2023). In Silico and In Vitro Inhibition of SARS-CoV-2 PLpro with Gramicidin D. in International Journal of Molecular Sciences, 24(3), 1955.
https://doi.org/10.3390/ijms24031955
Protić S, Kaličanin N, Senćanski M, Prodanović O, Milićević JS, Perović V, Paessler S, Prodanović R, Glišić S. In Silico and In Vitro Inhibition of SARS-CoV-2 PLpro with Gramicidin D. in International Journal of Molecular Sciences. 2023;24(3):1955.
doi:10.3390/ijms24031955 .
Protić, Sara, Kaličanin, Nevena, Senćanski, Milan, Prodanović, Olivera, Milićević, Jelena S., Perović, Vladimir, Paessler, Slobodan, Prodanović, Radivoje, Glišić, Sanja, "In Silico and In Vitro Inhibition of SARS-CoV-2 PLpro with Gramicidin D" in International Journal of Molecular Sciences, 24, no. 3 (2023):1955,
https://doi.org/10.3390/ijms24031955 . .
1
1